This site is intended for health professionals only
Wednesday 29 July 2015
Share |

New data on Bayer’s Xarelto®

Related articles

Full results from Kids B-LONG Alprolix® paediatric study to be released for the first time. Interim findings to be presented from ASPIRE, an open label extension study with Eloctate®/Elocta® in adults and children with haemophilia A
Amgen to advance understanding of the treatment of blood cancers at 20th Congress of European Hematology Association (EHA)
Fully automated instrument speeds workflow for fast, efficient results
Children living with haemophilia sometimes have a hard time talking about their condition or describing the implications the disease has on their life
New Haemo Control uniquely ensures bi-directional data management future proofing
Bayer HealthCare announced that new data from the clinical development programme for its oral anticoagulant Xarelto® (rivaroxaban) will be presented at the 54th American Society of Haematology (ASH) Annual Meeting and Exposition in Atlanta, GA, USA, December 8-11, 2012. These data underscore the benefits of rivaroxaban for patients at risk of dangerous blood clots across multiple venous thromboembolic conditions.
Notable data analyses to be presented at ASH 2012 include:

Ads by Google